|
1
|
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn
PA, Minna JD and Gallo RC: Detection and isolation of type C
retrovirus particles from fresh and cultured lymphocytes of a
patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA.
77:7415–7419. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hinuma Y, Nagata K, Hanaoka M, Nakai M,
Matsumoto T, Kinoshita KI, Shirakawa S and Miyoshi I: Adult T-cell
leukemia: Antigen in an ATL cell line and detection of antibodies
to the antigen in human sera. Proc Natl Acad Sci USA. 78:6476–6480.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yoshida M, Miyoshi I and Hinuma Y:
Isolation and characterization of retrovirus from cell lines of
human adult T-cell leukemia and its implication in the disease.
Proc Natl Acad Sci USA. 79:2031–2035. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bazarbachi A, Suarez F, Fields P and
Hermine O: How I treat adult T-cell leukemia/lymphoma. Blood.
118:1736–1745. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ishitsuka K and Tamura K: Human T-cell
leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet
Oncol. 15:e517–e526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Banerji U: Heat shock protein 90 as a drug
target: Some like it hot. Clin Cancer Res. 15:9–14. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hong DS, Banerji U, Tavana B, George GC,
Aaron J and Kurzrock R: Targeting the molecular chaperone heat
shock protein 90 (HSP90): Lessons learned and future directions.
Cancer Treat Rev. 39:375–387. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan P, Qing G, Qu Z, Wu CC, Rabson A and
Xiao G: Targeting autophagic regulation of NFkappaB in HTLV-I
transformed cells by geldanamycin: Implications for therapeutic
interventions. Autophagy. 3:600–603. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurashina R, Ohyashiki JH, Kobayashi C,
Hamamura R, Zhang Y, Hirano T and Ohyashiki K: Anti-proliferative
activity of heat shock protein (Hsp) 90 inhibitors via
beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer
Lett. 284:62–70. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ikebe E, Kawaguchi A, Tezuka K, et al:
Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes
tumor-cell infiltration into multiple organs and improves survival
period for ATL model mice. Blood Cancer J. 3:e1322013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Banerji U, O'Donnell A, Scurr M, Pacey S,
Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M,
et al: Phase I pharmacokinetic and pharmacodynamic study of
17-allylamino, 17-demethoxygeldanamycin in patients with advanced
malignancies. J Clin Oncol. 23:4152–4161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramanathan RK, Egorin MJ, Erlichman C, et
al: Phase I pharmacokinetic and pharmacodynamic study of
17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor
of heat-shock protein 90, in patients with advanced solid tumors. J
Clin Oncol. 28:1520–1526. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kelland LR, Sharp SY, Rogers PM, Myers TG
and Workman P: DT-diaphorase expression and tumor cell sensitivity
to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat
shock protein 90. J Natl Cancer Inst. 91:1940–1949. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eccles SA, Massey A, Raynaud FI, Sharp SY,
Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall
F, et al: NVP-AUY922: A novel heat shock protein 90 inhibitor
active against xenograft tumor growth, angiogenesis, and
metastasis. Cancer Res. 68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jensen MR, Schoepfer J, Radimerski T,
Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R,
Drysdale MJ, et al: NVP-AUY922: A small molecule HSP90 inhibitor
with potent antitumor activity in preclinical breast cancer models.
Breast Cancer Res. 10:R332008. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kamihira S, Atogami S, Sohda H, Momita S,
Yamada Y and Tomonaga M: Significance of soluble interleukin-2
receptor levels for evaluation of the progression of adult T-cell
leukemia. Cancer. 73:2753–2758. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishioka C, Takemoto S, Kataoka S,
Yamanaka S, Moriki T, Shoda M, Watanabe T and Taguchi H: Serum
level of soluble CD30 correlates with the aggressiveness of adult
T-cell leukemia/lymphoma. Cancer Sci. 96:810–815. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu W and Neckers L: Targeting the
molecular chaperone heat shock protein 90 provides a multifaceted
effect on diverse cell signaling pathways of cancer cells. Clin
Cancer Res. 13:1625–1629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Taniguchi H, Hasegawa H, Sasaki D, Ando K,
Sawayama Y, Imanishi D, Taguchi J, Imaizumi Y, Hata T, Tsukasaki K,
et al: Heat shock protein 90 inhibitor NVP-AUY922 exerts potent
activity against adult T-cell leukemia-lymphoma cells. Cancer Sci.
105:1601–1608. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sessa C, Shapiro GI, Bhalla KN, Britten C,
Jacks KS, Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA,
Akimov M, et al: First-in-human phase I dose-escalation study of
the HSP90 inhibitor AUY922 in patients with advanced solid tumors.
Clin Cancer Res. 19:3671–3680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Doi T, Onozawa Y, Fuse N, Yoshino T,
Yamazaki K, Watanabe J, Akimov M, Robson M, Boku N and Ohtsu A:
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in
Japanese patients with advanced solid tumors. Cancer Chemother
Pharmacol. 74:629–636. 2014. View Article : Google Scholar : PubMed/NCBI
|
